EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Impact of Diabetes on the Efficacy of Low‐Voltage Area Ablation for Persistent Atrial Fibrillation: A Subanalysis of the SUPPRESS‐AF Trial

Tatsuhisa Ozaki iD, Koichi Inoue iD, Tsuyoshi Mishima, Takuya Ohashi, Satoshi Osaki, Yasunori Ueda iD, Masaharu Masuda iD, Akihiro Sunaga iD, Nobuaki Tanaka iD, Tetsuya Watanabe iD, Hitoshi Minamiguchi, Yasuyuki Egami iD und 14 weitere

Journal of the American Heart Association · 2026

DOI: 10.1161/jaha.125.047450 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Tatsuhisa Ozaki und 25 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Division National Hospital Organization Osaka National Hospital Osaka Japan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Pulmonary Veins, Diabetes Mellitus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The potential value of low‐voltage area (LVA) ablation for persistent atrial fibrillation (AF) has been suggested. However, its efficacy determinants remain unclear. We investigated the impact of diabetes on the outcomes of LVA ablation in patients with persistent AF.

Methods

This post hoc subanalysis of the multicenter randomized controlled trial SUPPRESS‐AF (Efficacy and Safety of Low‐Voltage‐Guided Ablation for Recurrence Prevention Compared With Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation) included patients with persistent AF undergoing initial ablation. Following pulmonary vein isolation (PVI), patients with LVAs were randomized to PVI+LVA‐ablation or PVI alone. We compared recurrence‐free survival between patients with and without diabetes. The primary end point was freedom from AF/atrial tachycardia recurrence.

Results

Of 1347 patients with persistent AF, 343 (25.5%) had left atrial LVAs. The nondiabetic group comprised 264 patients (136 and 128 in the PVI‐alone and PVI+LVA‐ablation arms, respectively), and the diabetic group comprised 77 patients (35 and 42 in each arm, respectively). No significant difference was observed in LVA extent between the groups. Overall recurrence rates were also similar (44% versus 42%; P =0.658). In the nondiabetic group, the PVI+LVA‐ablation arm showed significantly lower recurrence rates compared with the PVI‐alone arm (35% versus 49%; P =0.018). Conversely, patients with diabetes exhibited higher recurrence rates in the PVI+LVA‐ablation arm compared with those in the PVI‐alone arm (48% versus 40%; P =0.290). A significant interaction was observed between diabetes status and LVA ablation efficacy ( P for interaction=0.041).

Conclusions

In this exploratory post hoc analysis, LVA ablation may benefit patients without diabetes, whereas no clear benefit, and a possible signal of futility, was observed in patients with diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationPulmonary VeinsDiabetes MellitusHumansFemaleMaleMiddle AgedRecurrenceTreatment OutcomeAgedTime FactorsRisk Factors

Stichwörter der Autor:innen

catheter ablationdiabeteslow‐voltage areapersistent atrial fibrillationrandomized controlled trial

Autor:innen und Institutionen

  • Cardiovascular Division National Hospital Organization Osaka National Hospital Osaka Japan.
  • Cardiovascular Center Kansai Rosai Hospital Amagasaki Japan.
  • Department of Cardiovascular Medicine Osaka University Graduate School of Medicine Suita Japan.
  • Cardiovascular Center Sakurabashi Watanabe Advanced Healthcare Hospital Osaka Japan.
  • Department of Cardiovascular Medicine Yao Municipal Hospital Yao Japan.
  • Cardiovascular Division, Osaka International Medical and Science Center Osaka Keisatsu Hospital Osaka Japan.

ORCID-Profile: Tatsuhisa Ozaki, Koichi Inoue, Yasunori Ueda, Masaharu Masuda, Akihiro Sunaga, Nobuaki Tanaka, Tetsuya Watanabe, Yasuyuki Egami, Takafumi Oka, Takashi Kanda, Masato Okada, Yasuhiro Matsuda, Koji Tanaka, Nobuhiko Makino, Hirota Kida, Shungo Hikoso, Tomoharu Dohi, Yohei Sotomi, Yasushi Sakata

Zitieren

APA

Ozaki, T., Inoue, K., Mishima, T., Ohashi, T., Osaki, S., Ueda, Y., Masuda, M., Sunaga, A., Tanaka, N., Watanabe, T., Minamiguchi, H., Egami, Y., Oka, T., Minamisaka, T., Kanda, T., Okada, M., Kawasaki, M., Matsuda, Y., Tanaka, K., …, & OCVC‐SUPPRESS‐AF investigators * (2026). Impact of Diabetes on the Efficacy of Low‐Voltage Area Ablation for Persistent Atrial Fibrillation: A Subanalysis of the SUPPRESS‐AF Trial. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.047450

Vancouver

Ozaki T, Inoue K, Mishima T, Ohashi T, Osaki S, Ueda Y, et al. Impact of Diabetes on the Efficacy of Low‐Voltage Area Ablation for Persistent Atrial Fibrillation: A Subanalysis of the SUPPRESS‐AF Trial. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.047450

BibTeX
@article{Ozaki2026,
  author = {Ozaki, Tatsuhisa and Inoue, Koichi and Mishima, Tsuyoshi and Ohashi, Takuya and Osaki, Satoshi and Ueda, Yasunori and Masuda, Masaharu and Sunaga, Akihiro and Tanaka, Nobuaki and Watanabe, Tetsuya and Minamiguchi, Hitoshi and Egami, Yasuyuki and Oka, Takafumi and Minamisaka, Tomoko and Kanda, Takashi and Okada, Masato and Kawasaki, Masato and Matsuda, Yasuhiro and Tanaka, Koji and Makino, Nobuhiko and Kida, Hirota and Hikoso, Shungo and Dohi, Tomoharu and Sotomi, Yohei and Sakata, Yasushi and OCVC‐SUPPRESS‐AF investigators *, OCVC‐SUPPRESS‐AF investigators *},
  title = {Impact of Diabetes on the Efficacy of Low‐Voltage Area Ablation for Persistent Atrial Fibrillation: A Subanalysis of the SUPPRESS‐AF Trial},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.125.047450}
}
Kostenlos starten →